| Literature DB >> 28863780 |
Mimount Bourfiss1,2, Davis M Vigneault1,3,4, Mounes Aliyari Ghasebeh5, Brittney Murray6, Cynthia A James6, Crystal Tichnell6, Firdaus A Mohamed Hoesein7, Stefan L Zimmerman5, Ihab R Kamel5, Hugh Calkins6, Harikrishna Tandri6, Birgitta K Velthuis7, David A Bluemke1, Anneline S J M Te Riele8,9,10.
Abstract
BACKGROUND: Regional right ventricular (RV) dysfunction is the hallmark of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C), but is currently only qualitatively evaluated in the clinical setting. Feature Tracking Cardiovascular Magnetic Resonance (FT-CMR) is a novel quantitative method that uses cine CMR to calculate strain values. However, most prior FT-CMR studies in ARVD/C have focused on global RV strain using different software methods, complicating implementation of FT-CMR in clinical practice. We aimed to assess the clinical value of global and regional strain using FT-CMR in ARVD/C and to determine differences between commercially available FT-CMR software packages.Entities:
Keywords: Arrhythmogenic right ventricular dysplasia/Cardiomyopathy; Feature tracking cardiac magnetic resonance imaging; Global myocardial strain; Regional myocardial strain; Software comparison study
Mesh:
Year: 2017 PMID: 28863780 PMCID: PMC5581480 DOI: 10.1186/s12968-017-0380-4
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Fig. 1Representative right ventricular segmentation used in Feature Tracking Cardiac Magnetic Resonance Imaging. Abbreviations: ST = subtricuspid region; AW = anterior wall region; AP = apical region
Baseline characteristics of the study population
| OVERT ARVD/C | Preclinical ARVD/C ( | Controls | |
|---|---|---|---|
| Female (%) | 22 (56) | 18 (45) | 14 (45) |
| Age (yrs) | 32.3 ± 13.5 | 31.3 ± 18.1 | 37.2 ± 14.9 |
| Global CMR parameters | |||
| RV EDV/BSA (mL/m2) | 88.3 ± 25.6a | 68.4 ± 14.4 | 69.7 ± 12.9 |
| RV ESV/BSA (mL/m2) | 47.4 ± 24.9a | 31.1 ± 9.8 | 30.0 ± 8.6 |
| RV EF (%) | 48.3 ± 11.7a | 54.9 ± 9.6 | 56.9 ± 9.7 |
| LV EDV/BSA (mL/m2) | 77.4 ± 12.1 | 69.1 ± 12.9 | 73.5 ± 9.6 |
| LV ESV/BSA (mL/m2) | 30.6 ± 9.5 | 25.2 ± 7.0 | 30.9 ± 15.1 |
| LV EF (%) | 62.7 ± 6.3 | 63.2 ± 11.7 | 58.9 ± 13.3 |
| Clinical Phenotype | |||
| Repolarization criteria | - | ||
| Major | 36 (93) | 1 (3) | |
| Minor | 22 (54) | 19 (48) | |
| Depolarization criteria | - | ||
| Major | 3 (8) | 0 (0) | |
| Minor | 19 (49) | 18 (45) | |
| Arrhythmia criteria | - | ||
| Major | 7 (18) | 0 (0) | |
| Minor | 26 (67) | 4 (10) | |
| Structural criteria | - | ||
| Major | 16 (41) | 0 (0) | |
| Minor | 7 (18) | 0 (0) | |
| TFC fulfillment: number of criteria (median) | 6 (IQR 5–7) | 2 (IQR 2–3) | - |
Abbreviations: ARVD/C Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy, BSA Body Surface Area, EDV End-Diastolic Volume, EF Ejection Fraction, ESV End-Systolic Volume, TFC Task Force Criteria, N number of subjects
a Statistical significant difference compared to control subjects
Fig. 2Percentage of cases with adequate tracking quality of the endocardial border stratified per segment and software method
Right ventricular global (average) strain values stratified by diagnostic groupd
| Overt ARVD/C ( | Preclinical ARVD/C ( | Controls | P-Valuec | |
|---|---|---|---|---|
| MEDIS | −17.6 ± 6.3ab | −21.8 ± 4.6 | −21.4 ± 5.5 | 0.001 |
| TOMTEC | −14.3 ± 7.1ab | −17.7 ± 6.6 | −17.8 ± 5.6 | 0.057 |
| MTT | −19.3 ± 6.2ab | −26.2 ± 5.0 | −27.7 ± 5.5 | <0.001 |
| CIRCLE | −21.3 ± 5.3 a | −22.9 ± 3.7 | −23.7 ± 2.3 | 0.065 |
a Statistical significant difference compared to control subjects; b = Statistical significant difference compared to preclinical subjects; c = Trend between overt ARVD/C patients, preclinical ARVD/C and control subjects (OneWay ANOVA). Abbreviations: ARVD/C = Arrhythmogenic Right Ventricular Dysplasia/ Cardiomyopathy; MTT = Multimodality Tissue Tracking; N = number of subjects
d Segments included based on adequate tracking quality: 365/438, 429/468, and 328/360 segments in overt ARVD/C, preclinical ARVD/C and control subjects respectively
Fig. 3Bland-Altman plots per intersoftware variability of average right ventricular strain values. Intersoftware variability of strain values in a) Medis vs. MTT; b) Medis vs. TomTec; c) MTT vs. TomTec; d) Circle vs. Medis; e) Circle vs. TomTec; f) Circle vs. MTT
Fig. 4Global (average) strain by group per software package. Statistical significant difference compared to control subjects is expressed in * = p < 0.05 and ** = p < 0.01. Abbreviations: MTT = Multimodality Tissue Tracking
Right ventricular regional (segmental) strain values stratified by diagnostic groupd
| Overt ARVD/C ( | Preclinical ARVD/C ( | Controls | P-Valuec | |
|---|---|---|---|---|
| Subtricuspid Region | ||||
| MEDIS | −-28.4 ± 14.8a | −31.6 ± 10.4a | −38.1 ± 8.1 | 0.007 |
| TOMTEC | −24.7 ± 18.3a | −32.4 ± 12.6 | −34.3 ± 11.4 | 0.045 |
| MTT | −24.4 ± 10.8ab | −33.4 ± 10.9 | −36.9 ± 10.5 | <0.001 |
| CIRCLE | −23.0 ± 8.4a | −26.2 ± 6.3 | −27.0 ± 5.0 | 0.067 |
| Anterior Wall Region | ||||
| MEDIS | −20.6 ± 10.5ab | −28.6 ± 10.3 | −29.0 ± 11.1 | 0.001 |
| TOMTEC | −17.5 ± 11.9 | −19.7 ± 11.1 | −22.6 ± 12.5 | 0.248 |
| MTT | −17.7 ± 6.4 ab | −23.0 ± 6.1 | −22.8 ± 6.3 | 0.001 |
| CIRCLE | −22.8 ± 6.2 | −24.2 ± 5.0 | −25.3 ± 3.4 | 0.168 |
| Apical Region | ||||
| MEDIS | −22.8 ± 10.0b | −27.8 ± 8.7 | −25.1 ± 9.6 | 0.072 |
| TOMTEC | −12.7 ± 10.7 | −14.7 ± 10.4 | −13.1 ± 8.6 | 0.674 |
| MTT | −18.6 ± 8.8ab | −23.3 ± 7.8 | −25.5 ± 9.6 | 0.019 |
| CIRCLE | −18.3 ± 5.4 | −19.9 ± 5.1 | −19.5 ± 5.6 | 0.521 |
a Statistical significant difference compared to control subjects; b Statistical significant difference compared to preclinical subjects; c Trend between overt ARVD/C patients, preclinical ARVD/C and control subjects (OneWay ANOVA). Abbreviations: ARVD/C = Arrhythmogenic Right Ventricular Dysplasia/ Cardiomyopathy; MTT = Multimodality Tissue Tracking; N = number of subjects
dSegments included based on adequate tracking quality: 365/438, 429/468, and 328/360 segments in overt ARVD/C, preclinical ARVD/C and control subjects respectively
Fig. 5Bland-Altman plots per intersoftware variability of right ventricular subtricuspid strain values. Intersoftware variability of strain values in the subtricuspid region in a) Medis vs. MTT; b) Medis vs. TomTec; c) MTT vs. TomTec; d) Circle vs. Medis; e) Circle vs. TomTec; f) Circle vs. MTT. ST = subtricuspid region
Fig. 6Regional strain by subgroup per software package. Statistical significant difference compared to control subjects is expressed in * = p < 0.05 and * = p < 0.01. Abbreviations: ST = subtricuspid region; AW = anterior wall region; AP = apical region; MTT = Multimodality Tissue Tracking
Intra- and inter-observer reproducibility of regional (segmental) strain per software method
| Intra-Observer ICC | Inter-Observer ICC | |
|---|---|---|
| Subtricuspid Region | ||
| MEDIS | 0.928 | 0.896 |
| TOMTEC | 0.816 | 0.538 |
| MTT | 0.696 | 0.519 |
| CIRCLE | 0.980 | 0.719 |
| Anterior Wall Region | ||
| MEDIS | 0.954 | 0.792 |
| TOMTEC | 0.699 | 0.864 |
| MTT | 0.806 | 0.677 |
| CIRCLE | 0.969 | 0.783 |
| Apical Region | ||
| MEDIS | 0.909 | 0.807 |
| TOMTEC | 0.790 | 0.861 |
| MTT | 0.787 | 0.472 |
| CIRCLE | 0.944 | 0.577 |
An ICC ≥0.75 was considered excellent, an ICC between <0.75 and ≥0.40 moderate, and an ICC <0.40 poor. Abbreviations: MTT = Multimodality Tissue Tracking; ICC = Intraclass Correlation Coefficient